Zeynep Tufekci helps me understand the systems-wide failure on Covid — and how we can prepare for the pandemic’s next phase. Produced by ‘The Ezra Klein Show’ I remember thinking, as Covid ravaged the country in December 2020, that at least the holidays the next year would be better. There would be more vaccines, more treatments, more immunity. Instead, we […]

Here’s what you need to know about the week’s top stories. Send any friend a story As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share. By Remy Tumin (Want to get this briefing by email? Here’s the sign-up.) Here are the week’s top stories, and a look ahead. 1. The U.S. […]

Send any friend a story As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share. By Lindsay Crouse Ms. Crouse is a writer and producer in Opinion who writes on gender, ambition and power. What’s worse than an anti-vaxxer in a pandemic? An anti-vaccine star athlete. That paragon of physical health, cloaked […]

Send any friend a story As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share. By Michelle Cottle Ms. Cottle is a member of the editorial board. Well, that was weird. Much of the past 12 months felt as though 2021 came about by looking at the political insanity of 2020 and […]

Supported by Send any friend a story As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share. Video by Lindsay Crouse, Kirby Ferguson and Emily Holzknecht Ms. Crouse is a writer and producer in Opinion. Mr. Ferguson is a documentary filmmaker. Ms. Holzknecht is an associate producer in Opinion. That’s right: We’re all […]

FILE PHOTO: The Shinsei Bank logo is pictured at the lobby of the bank in Tokyo, Oct. 22, 2010. REUTERS/Yuriko NakaoTOKYO (Reuters) -Government-owned Deposit Insurance Corp of Japan is planning to vote against Shinsei Bank’s poison pill defence aimed at blocking SBI Holdings Inc’s $1.1 billion bid, public broadcaster NHK reported on Tuesday. How the government votes on the defence […]

(Reuters) -French biopharmaceutical company Abionyx Pharma said on Wednesday it had signed a deal to buy the owner of ophthalmological group IRIS Pharma. Abionyx said it would fully finance the deal, which values IRIS Pharma Holding at 5 million euros ($5.66 million), through a capital hike that aims to raise around the same amount. “Abionyx will have the means to […]